Phase I trial of PBI 4050 in healthy volunteers (first-in-man trial)
Phase of Trial: Phase I
Latest Information Update: 09 Nov 2015
Price : $35 *
At a glance
- Drugs Setogepram (Primary)
- Indications Diabetic nephropathies; Renal fibrosis
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors ProMetic Life Sciences
- 09 Nov 2015 Results from this phase I study have been presented at the American Society of Nephrology (ASN) annual meeting.
- 11 Sep 2014 New trial record
- 03 Sep 2014 Results published in the Media Release.